These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34502377)

  • 21. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.
    Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z
    Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
    Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
    Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
    Ekblad L; Kjellström J; Johnsson A
    Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
    Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gel electrophoresis in combination with laser ablation-inductively coupled plasma mass spectrometry to quantify the interaction of cisplatin with human serum albumin.
    Sullivan MP; Morrow SJ; Goldstone DC; Hartinger CG
    Electrophoresis; 2019 Sep; 40(18-19):2329-2335. PubMed ID: 31087392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Cisplatin Efficacy on HepG2 and E. coli Cells under Acidic Conditions.
    Babaei F; Ebrahimi Shahmabadi H; Rajabi MR; Haddad Kashani H; Izadpanah F
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):723-726. PubMed ID: 30909670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines.
    Rimoldi I; Coccè V; Facchetti G; Alessandri G; Brini AT; Sisto F; Parati E; Cavicchini L; Lucchini G; Petrella F; Ciusani E; Pessina A
    Biomed Pharmacother; 2018 Dec; 108():111-118. PubMed ID: 30218855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanical stress promotes cisplatin-induced hepatocellular carcinoma cell death.
    Ziko L; Riad S; Amer M; Zdero R; Bougherara H; Amleh A
    Biomed Res Int; 2015; 2015():430569. PubMed ID: 25685789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-resolution imaging and single-cell analysis via laser ablation-inductively coupled plasma-mass spectrometry for the determination of membranous receptor expression levels in breast cancer cell lines using receptor-specific hybrid tracers.
    Van Acker T; Buckle T; Van Malderen SJM; van Willigen DM; van Unen V; van Leeuwen FWB; Vanhaecke F
    Anal Chim Acta; 2019 Oct; 1074():43-53. PubMed ID: 31159938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.
    Espina M; Corte-Rodríguez M; Aguado L; Montes-Bayón M; Sierra MI; Martínez-Camblor P; Blanco-González E; Sierra LM
    Metallomics; 2017 May; 9(5):564-574. PubMed ID: 28425536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects after treatment with platinum compounds, cisplatin and [Pt(O,O'-acac)(γ-acac)(DMS)]: Autophagy activation in rat B50 neuroblastoma cells.
    Grimaldi M; Bo VD; Ferrari B; Roda E; De Luca F; Veneroni P; Barni S; Verri M; De Pascali SA; Fanizzi FP; Bernocchi G; Bottone MG
    Toxicol Appl Pharmacol; 2019 Feb; 364():1-11. PubMed ID: 30529627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Assessment of Cisplatin/Hyaluronan Complex for Loco-Regional Chemotherapy.
    Banella S; Saraswat A; Patel A; Serajuddin ATM; Colombo P; Patel K; Colombo G
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity.
    Ferraro G; Sanfilippo V; Chiaverini L; Satriano C; Marzo T; Merlino A; La Mendola D
    Dalton Trans; 2023 Jul; 52(26):9058-9067. PubMed ID: 37337706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular accumulation of thallium as a marker of cisplatin cytotoxicity in nonsmall cell lung carcinoma: an application of inductively coupled plasma mass spectrometry.
    Hanada T; Isobe H; Saito T; Ogura S; Takekawa H; Yamazaki K; Tokuchi Y; Kawakami Y
    Cancer; 1998 Sep; 83(5):930-5. PubMed ID: 9731897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric analysis of the effectiveness of cisplatin on cutaneous squamous carcinoma cells using two different types of adjuvants.
    Gil S; Solano E; Martínez-Trucharte F; Martínez-Esaín J; Pérez-Berná AJ; Conesa JJ; Kamma-Lorger C; Alsina M; Sabés M
    PLoS One; 2020; 15(3):e0230022. PubMed ID: 32143211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.